Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2014

View Archived Issues

Apceth begins first human trial of genetically modified MSCs in cancer

Experience with tau-binding radiotracer [18F]T-807 accumulates

CHMP issues opinion on ataluren in nonsense mutation DMD

Researchers at Lundbeck present new nAChR PAMs

Endocyte provides update on MAAs for vintafolide and etarfolatide

GSK receives positive CHMP opinion for albiglutide in type 2 diabetes

Novel orexin receptor antagonists designed at Heptares Therapeutics

GSK reports data from phase III study of Tafinlar and Mekinist in melanoma

Canadian group discloses novel BTK inhibitors

hHR21 expression linked to prognosis in patients with colorectal cancer

Japanese researchers divulge new sst2 receptor agonists

Researchers at Esteve have patented novel sigma1R ligands

Crown Bioscience discloses novel kinase inhibitors for cancer

NIBIO, Aeras and Create form global collaboration to advance new mucosal TB vaccines

EMA committee recommends approval of Finox Biotech's biosimilar FSH

Roche's subcutaneous MabThera recommended for approval by CHMP

Lurasidone recommended for treatment of schizophrenia by EMA advisory committee

EMA committee recommends against approval of Nerventra for relapsing-remitting MS

Pacgen to sublicense global rights to antimicrobial peptide to GBC

mRNAs investigated as biomarkers in pancreatic neuroendocrine tumors

EMA committee advises against approval of masitinib for advanced pancreatic cancer

Nihon Medi-Physics launches DatSCAN in Japan

Phase I/II study of OPB-111001 recruiting patients with advanced cancer

Phase I study of novel treatment candidate for alcoholism begins patient recruitment

EMA committee recommends approval of Bayer's riociguat for two forms of pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...